The Roche Group said its candidate antibody for haematological cancers, obinutuzumab, met its primary endpoint in the first stage of a Phase 3 trial and will now move on to be compared directly with MabThera/Rituxan (rituximab), the standard of care for leukaemias and lymphomas.
